Study defines key driver of aggressive ovarian cancer
Peer-Reviewed Publication
Updates every hour. Last Updated: 13-Sep-2025 13:11 ET (13-Sep-2025 17:11 GMT/UTC)
Researchers from the University of Michigan Rogel Cancer Center developed a new mouse model that shows CDK12 acts as a tumor suppressor to drive high-grade serous carcinoma arising in the mouse oviduct – the equivalent of human fallopian tube. A promising degrader targeting CDK12 and a related gene, CDK13, can destroy these tumors.
As recommendations suggest extending hormone-based breast cancer treatment to 10 years for some patients, a new study sheds light on whether patients are opting for it. In a study of 591 women with early stage breast cancer who completed five years of endocrine therapy, 47% decided to continue the treatment.